Eckert & Ziegler confirms guidance. Eckert & Ziegler stock sits 34.95 percent below its high.

Published on 10/06/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue was EUR 149.30 million while adjusted EBIT fell 6.00 percent. Eckert & Ziegler stock costs EUR 12.21 after EUR 12.08 on October 6, 2026.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) was trading at EUR 12.21 at Lang & Schwarz on October 6, 2026 at 3:36 p.m. CEST, up 1.08 percent from the prior close of EUR 12.08. The stock was 34.95 percent below its 52-week high of EUR 18.77, while Quartr reported on September 25, 2026 that the company had kept its 2026 guidance unchanged.

Guidance stays at EUR 320 million

The 2026 outlook calls for group sales of EUR 320.0 million and adjusted EBIT of EUR 80.0 million. Those targets imply growth of 3.00 percent for both measures, according to Quartr.

The guidance sits against a mixed first-half picture. Revenue was EUR 149.3 million in the first half of 2026, unchanged from the first half of 2025, while adjusted EBIT fell 6.00 percent to EUR 33.3 million. Net income increased 5.00 percent to EUR 22.4 million in the same period.

Medical outperforms isotope products

Segment performance explains the gap between sales and operating profit. Medical posted 7.00 percent EBIT growth in the first half of 2026, while Isotope Products recorded a 24.00 percent EBIT decline, according to Quartr.

Eckert & Ziegler operates in two segments, Medical and Isotope Products, supplying isotope technology for cancer treatment, nuclear medicine diagnostics and industrial radiometry, according to the company investor-relations page. The Medical segment therefore carries the clearest operating support for the 2026 target, while the Isotope Products decline remains the central execution issue.

Berenberg target stands at EUR 23

Trading-Treff reported on August 26, 2026 that Berenberg maintained a Buy rating and a EUR 23.00 price target. Relative to the Lang & Schwarz price of EUR 12.21 on October 6, 2026, that target is 88.37 percent above the reference price.

The next scheduled reporting event is the third-quarter 2026 earnings release on November 12, 2026, according to MarketScreener. That report will show whether the second-half recovery assumed in the guidance is translating into higher operating profit.

Stock remains below its yearly high

Eckert & Ziegler had a market capitalization of EUR 763.4 million as of October 6, 2026 at 3:25 p.m. CEST. The 52-week range was EUR 12.17 to EUR 18.77 on September 16, 2026, leaving the current Lang & Schwarz price EUR 0.04 above the lower end of that range. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.